Profile data is unavailable for this security.
About the company
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
- Revenue in USD (TTM)0.00
- Net income in USD-117.67m
- Incorporated2015
- Employees65.00
- LocationAthira Pharma Inc18706 North Creek ParkwaySuite 104, Box 352141BOTHELL 98011United StatesUSA
- Phone+1 (425) 620-8501
- Fax+1 (302) 636-5454
- Websitehttps://www.athira.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | 1.76m | -153.05m | 79.94m | 74.00 | -- | -- | -- | 45.52 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Precision BioSciences Inc | 57.53m | -19.99m | 80.37m | 109.00 | -- | 2.16 | -- | 1.40 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| Elutia Inc | 24.75m | -41.25m | 81.33m | 54.00 | -- | -- | -- | 3.29 | -2.20 | -2.08 | 1.35 | -1.66 | 0.4408 | 1.97 | 4.90 | 458,240.80 | -73.48 | -42.93 | -309.94 | -79.34 | 44.67 | 43.32 | -166.70 | -64.16 | 0.6367 | -3.54 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 81.51m | 4.00 | -- | -- | -- | 146.16 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -102.06m | 81.64m | 58.00 | -- | 0.6542 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Aileron Therapeutics Inc | 0.00 | -15.73m | 82.45m | 15.00 | -- | 2.77 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Gritstone bio Inc | 15.65m | -144.89m | 82.65m | 231.00 | -- | 5.35 | -- | 5.28 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 84.09m | 91.00 | -- | 0.592 | -- | 2.70 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Athira Pharma Inc | 0.00 | -117.67m | 84.32m | 65.00 | -- | 0.6451 | -- | -- | -3.09 | -3.09 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -56.25 | -30.73 | -63.93 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Spero Therapeutics Inc | 103.78m | 22.81m | 86.23m | 46.00 | 3.95 | 0.7933 | 3.72 | 0.8309 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Allovir Inc | 0.00 | -190.42m | 88.72m | 112.00 | -- | 0.6046 | -- | -- | -1.83 | -1.83 | 0.00 | 1.28 | 0.00 | -- | -- | 0.00 | -81.40 | -52.85 | -91.73 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 88.74m | 20.00 | -- | 0.776 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Dec 2023 | 5.40m | 14.10% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 3.15m | 8.23% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.62m | 4.23% |
| Simplify Asset Management, Inc.as of 31 Dec 2023 | 1.49m | 3.90% |
| Propel Bio Management LLCas of 31 Dec 2023 | 1.49m | 3.90% |
| Tang Capital Management LLCas of 31 Dec 2023 | 1.15m | 3.01% |
| BML Capital Management LLCas of 31 Mar 2024 | 900.00k | 2.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 649.72k | 1.70% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 549.94k | 1.44% |
| Millennium Management LLCas of 31 Dec 2023 | 455.86k | 1.19% |
